Boussery K, De Smet J, De Cock P, Vande Velde S, Mehuys E, De Paepe P, Remon JP, Van Bocxlaer JFP, Van Winckel M. Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.
Br J Clin Pharmacol 2011;
72:990-6. [PMID:
21658093 DOI:
10.1111/j.1365-2125.2011.04038.x]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
AIMS
Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems.
METHODS
Nonblinded, two-phase cross-over trial.
RESULTS
In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS® formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS® over suspension) was 0.5 (0.06-2.37).
CONCLUSIONS
In this population, omeprazole MUPS® formulation has no apparent advantage over the more easily administered suspension formulation.
Collapse